SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Exelixis, Inc. (EXEL)
An SI Board Since January 2001
Posts SubjectMarks Bans Symbol
930 66 0 EXEL
Emcee:  kinkblot Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
155You could probably already tell but, of all competitor cpds, chir-258 appears tokeokalani'nui-6/2/2005
154thanks for putting that here! (eom)scaram(o)uche-6/2/2005
153Chiron and the Multiple Myeloma Research Consortium Announce Initiation of Phasekeokalani'nui-6/2/2005
152Tuck, I don't see arry and arql as comparable. Business model is much differrkrw-5/13/2005
151Here you go- an ARRY thread: Subject 55588Tomato-5/12/2005
150Getting further OT . . . You follow ARQL? Some have said it compares favortuck-5/12/2005
149Re: ARRY Somehow I ended up with a 1/2 position in arry myself. :-) But I dokeokalani'nui-5/12/2005
148Multi kinase approach should work better than 1st gen kinases because you get corkrw-5/12/2005
147GS: EXEL(IL/N): Q1 in line. Pipeline progressing well. Maintain 2005-07 estimatemopgcw-5/12/2005
146>>Feel for competing programs.<< Oh there are almost an infinite nukeokalani'nui-5/11/2005
145Charly of MF on EXEL: fool.com He notes that EXEL's cancer drugs all go aftuck-5/10/2005
144Exelixis Achieves $35 Million in Milestones From GSK Monday May 9, 6:00 am ET nigel bates-5/9/2005
143Exelixis Files IND Application for Novel Anticancer Compound XL844 Monday May 2,nigel bates-5/2/2005
142Exelixis Files IND Application for Novel Anticancer Compound XL820 Monday April nigel bates-4/25/2005
141Hate to say it, but it looks like exel's shareholders are using this nice bokeokalani'nui-4/21/2005
140dunno. not much. Agrinomics (EXEL acquired Bayer's interest in May 2004)..scaram(o)uche-4/1/2005
139<i>Bayer will pay Exelixis an early termination fee of approximately $10.9nigel bates-4/1/2005
138Item 1.02 Termination of a Material Definitive Agreement. On March 30, 2005,scaram(o)uche-4/1/2005
137<i>Pre-Planned Analysis of Progression-Free Survival as Assessed by Investkeokalani'nui-3/21/2005
136Exelixis Initiates Phase I Trial for Anticancer Compound XL880 Thursday March 17nigel bates-3/17/2005
135GS: EXEL(IL/N): Beat Q4 on lower expenses. Improve ?05 est. Steady progress on pmopgcw-2/18/2005
134rkrw: I think PGS is the one to ask about this. This is my last available post tDewDiligence_on_SI-2/17/2005
133>> Why the secrecy? << I believe, but am not certain, that we get sscaram(o)uche-2/17/2005
132Why the secrecy? If I'm assuming high, please do tell. GSK and Exelixis Rirkrw-2/17/2005
131You might want to talk to PGS about this.DewDiligence_on_SI-2/17/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News